Immunizzazione contro il virus sinciziale respiratorio nei bambini: l'antico, il nuovo e ciò che sta per arrivare.

Respiratory syncytial virus (RSV) remains a leading cause of severe lower respiratory tract infection, hospitalization, morbidity and mortality in young children. This review summarizes current RSV immunization strategies and parental perspectives on their use. Until recently, immunization was limited to high-risk infants and children, including those born prematurely or with significant co-morbidities, via monthly dosing with the monoclonal antibody (mAb) palivizumab. Recent approvals of long-acting mAb nirsevimab and the maternal RSV pre-fusion F vaccine combined with other anticipated options such as long-acting mAb clesrovimab, and future pediatric vaccines, signal a shift in RSV immuniz